Roger N. Morris quoted in article “Lawyers React To High Court’s Generic-Drug Liability Ruling”

Media Mention

Following is an excerpt:

The U.S. Supreme Court ruled 5-4 Monday that users of generic drugs cannot bring state-law design defect claims against generics makers because the manufacturers cannot change a drug's design under federal law. Here, attorneys tell Law360 why the ruling is significant.

Roger Morris, Quarles & Brady LLP
"Today's decision provides generic-drug makers with almost 'bulletproof' protection from tort liability when choosing to produce a generic drug. Not only are generic-drug makers immune from adequate warnings on labels — see Pliva v. Mensing — today the court holds generic-drug maker Mutual Pharmaceutical Co. Inc. harmless for alleged design defect of the active ingredient in its medication. Generic-drug consumers appear to have little to no remedy in tort claims against generic-drug makers. This may cause more patients to pause before requesting a generic drug from their pharmacist and a review of federal law by Congress."

Follow Quarles

Subscribe Media Contact
Back to Main Content

We use cookies to provide you with the best user experience on our website and to analyze statistics related to our website. To understand more about how we use cookies, or for instructions to change your preference and browser settings, please see our Privacy Notice. Please note that if you choose to reject cookies, doing so may impair some of our website's functionality.